Genetics Pioneer Dies

James Crow, who helped shaped public policy over his 70 year career, passed away last week.

By | January 12, 2012

UNIVERSITY OF WISCONSIN-MADISON

James Crow, an influential population geneticist at the University of Wisconsin-Madison, died of congestive heart failure last Wednesday at the age of 95, the New York Times reported. A leader in the field for more than 50 years, Crow helped shape public policy on major genetics issues such as atomic radiation damage and the use of DNA in the courtroom. He was active in the scientific community right up until his death, working on a new paper in his campus office just two weeks ago, the university reported.

“He was the real organizer of population genetics in the United States,” Will Provine, a historian of biology at Cornell University, told the Times. Crow’s 1970 landmark textbook, "An Introduction to Population Genetics Theory," co-authored with Motoo Kimura, laid much of the groundwork for the mathematical basis of population genetics theory.

Crow was a member of a National Academy of Sciences genetics committee tasked with assessing mutational damage in those exposed to radiation from the atomic bombs dropped on Hiroshima and Nagasaki. The committee’s concern about aboveground nuclear weapons testing led to the eventual ban on such activities in the United States and other countries. Crow also led a NAS committee in the 1990s that helped legitimize the use of DNA test results in the courtroom.

Crow was also an active public servant and an accomplished musician who played the viola in the Madison Symphony Orchestra from 1949-1994. He is survived by a son, two daughters, six grandchildren and two great-grandchildren.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Human Cord Plasma Protein Boosts Cognitive Function in Older Mice
AAAS